Epidermal Growth Factor Receptor Antagonist class drugs

2 results

  • erbitux

    (cetuximab)
    ImClone LLC
    ERBITUX is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), recurrent or metastatic SCCHN, K-Ras wild-type metastatic colorectal cancer (mCRC), and BRAF V600E mutation-positive mCRC in combination with specific therapies. It is not for Ras-mutant cancers.
    Medication Details
    Drug Interactions

  • portrazza

    (necitumumab)
    Eli Lilly and Company
    PORTRAZZAâ„¢ is indicated for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin. It is not intended for non-squamous NSCLC.
    Medication Details
    Drug Interactions